Equities

Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret A

ANGEN.E:IST

Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret A

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TRY)16.68
  • Today's Change0.530 / 3.28%
  • Shares traded50.43m
  • 1 Year change-6.82%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 16:09 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS is a Turkey-based company, which is s a biotechnology company operating in accordance with ISO 9001, ISO 13485 and 98/79/EC Total Quality Systems. The Company's main activities are to develop and produce Real-Time Polymerase Chain Reaction (Real-Time PCR) kits, and to create a complete solution with automatic nucleic acid isolation devices and Real-Time PCR Systems. The main goals of the entity are to reduce Turkey's foreign dependency in molecular diagnostics and biotechnology and to gain success in the global market by developing and producing molecular genetic products.

  • Revenue in TRY (TTM)305.50m
  • Net income in TRY-208.78m
  • Incorporated2010
  • Employees229.00
  • Location
    Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AEgitim Mah. Kasap Ismail Sk. No:10/23ISTANBUL 34722TurkeyTUR
  • Phone+90 2 163300455
  • Fax+90 2 163300042
  • Websitehttps://www.anatoliageneworks.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Arcticzymes Technologies ASA377.81m47.61m2.88bn68.0060.492.7842.697.630.28670.28672.276.240.34850.53496.831,706,250.004.3915.584.6317.2294.3996.6912.6033.2317.25--0.02980.00-13.1612.24-40.89--47.93--
Captor Therapeutics SA166.32m-416.56m3.09bn104.00--6.83--18.56-10.29-10.294.0810.870.2391--5.26179,230.80-59.88---83.65--51.97---250.46------0.1114--44.15---96.65------
Adocia SA81.91m-806.19m3.25bn78.00------39.67-1.93-1.930.194-0.49080.07742.627.4427,564.10-76.16-43.08-396.14-72.937.91---984.28-514.531.01-2.072.12---81.22-46.13-206.65---27.60--
Alligator Bioscience AB153.32m-785.95m3.36bn51.00------21.93-0.362-0.3620.0696-0.01250.2653--9.47788,034.50-136.02-73.26-367.94-91.33-----512.61-811.68---35.615.17--62.7816.60-28.53---20.34--
Inventiva SA665.81m-4.21bn3.60bn112.00------5.40-2.45-2.450.3854-0.61460.1884--9.18156,044.60-116.84-54.30-207.08-69.98-----620.31-669.970.9524-19.986.96--43.5040.46-103.46---0.33--
Anatolia TaniveBytklj Unli Ar Ge SiveTiA305.50m-208.78m3.67bn229.00--2.79--12.01-0.5563-0.55631.855.980.25490.34734.291,490,227.00-17.4216.60-18.3617.7280.5585.88-68.3439.695.78--0.0142---49.1472.60-548.82--65.06--
Maat Pharma SA84.88m-751.14m3.89bn50.00--4.17--45.85-1.73-1.730.1961.760.05084.844.1644,560.00-44.99-35.49-58.93-42.9874.28---884.96-1,157.542.76-49.610.4075--55.80---43.78--30.30--
Scope Fluidics SA829.81k-201.68m3.99bn40.00--6.03--4,807.02-8.29-8.290.034127.180.00092.940.03372,325.00-21.7652.74-22.7457.32-2,022.58-420.87-24,304.3030,134.7813.86--0.0299--27.72---105.76--89.99--
Eurofins-Cerep SA1.68bn291.01m4.11bn228.0014.131.6711.232.451,514.431,514.438,743.9412,820.370.58641.675.08193,287.1010.1614.2112.2217.5185.0173.6117.3319.774.87--0.00005---7.4711.60-33.7214.64----
Heidelberg Pharma AG362.76m-497.55m4.17bn97.00--2.66--11.50-0.2837-0.28370.20620.88320.12700.19413.23100,234.60-17.42-43.91-22.34-64.3482.7452.13-137.16-206.244.90--0.3417---46.7521.87-3.27---0.8341--
BenevolentAI SA221.33m-2.34bn4.24bn248.00--1.13--19.15-0.5111-0.51110.04840.68860.0401--0.171223,425.98-42.37---50.50---14.73---1,056.02------0.0594---30.58--61.38------
Egetis Therapeutics AB (publ)314.99m-994.28m4.50bn32.00--3.34--14.30-1.23-1.230.38841.370.149613.457.483,477,778.00-33.65-33.02-40.07-36.4692.12---224.92-357.721.55-24.390.2158--154.8715.35-68.68------
XSpray Pharma AB (publ)0.00-720.41m4.52bn26.00--2.48-----7.05-7.050.0019.790.00----0.00-33.11-18.38-36.76-19.26--------3.50--0.0496-------36.45--2.87--
Oryzon Genomics SA0.00-145.71m4.54bn43.00--1.34-----0.0597-0.05970.001.370.00153.65--0.00-3.55-4.20-4.13-4.82--------0.9495-3.540.134------20.76--15.52--
Diamyd Medical AB623.94k-468.37m4.70bn25.00--7.39--7,537.94-1.55-1.550.00211.960.0009--3.357,440.00-68.99-25.46-76.65-28.37-7,386.02-1,419.23-75,065.59-5,896.43---90.740.1391--20.26-5.54-12.13------
Data as of Sep 20 2024. Currency figures normalised to Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret A's reporting currency: Turkish Lira TRY

Institutional shareholders

0.21%Per cent of shares held by top holders
HolderShares% Held
Union Bancaire Priv�e, UBP SA (UK)as of 25 Jan 2023323.85k0.15%
Polunin Capital Partners Ltd.as of 31 Dec 2023128.33k0.06%
Dimensional Fund Advisors LPas of 05 Sep 202415.94k0.01%
American Century Investment Management, Inc.as of 05 Sep 2024390.000.00%
Schroder Investment Management Ltd.as of 31 Dec 20230.000.00%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.